FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3217012908> ?p ?o ?g. }

• W3217012908 endingPage "134" @default.
• W3217012908 startingPage "131" @default.
• W3217012908 abstract "Future Medicinal ChemistryVol. 14, No. 3 EditorialSelective CDK9 degradation using a proteolysis-targeting chimera (PROTAC) strategyJayapal Reddy Mallareddy‡, Sarbjit Singh‡, Lidia Boghean & Amarnath NatarajanJayapal Reddy Mallareddy‡ https://orcid.org/0000-0003-0440-6617Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA‡Authors contributed equallySearch for more papers by this author, Sarbjit Singh‡Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA‡Authors contributed equallySearch for more papers by this author, Lidia Boghean https://orcid.org/0000-0003-3830-3560Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USASearch for more papers by this author & Amarnath Natarajan *Author for correspondence: Tel.: +1 402 559 3793; E-mail Address: anatarajan@unmc.eduhttps://orcid.org/0000-0001-5067-0203Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USADepartment of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, USADepartment of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, NE 68198, USAFred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USASearch for more papers by this authorPublished Online:24 Nov 2021https://doi.org/10.4155/fmc-2021-0220AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: cancerCDK9degraderPROTACReferences1. Blake DR, Vaseva AV, Hodge RG et al. Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer. Sci. Signal. 12(590), eaav7259 (2019).Crossref, Medline, Google Scholar2. Sonawane YA, Taylor MA, Napoleon JV, Rana S, Contreras JI, Natarajan A. Cyclin dependent kinase 9 inhibitors for cancer therapy. J. Med. Chem. 59(19), 8667–8684 (2016).Crossref, Medline, CAS, Google Scholar3. Sakamoto KM, Kim KB, Kumagai A, Mercurio F, Crews CM, Deshaies RJ. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc. Natl Acad. Sci. USA 98(15), 8554–8559 (2001).Crossref, Medline, CAS, Google Scholar4. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer 9(3), 153–166 (2009).Crossref, Medline, CAS, Google Scholar5. Rana S, Mallareddy JR, Singh S et al. Inhibitors, PROTACs and molecular glues as diverse therapeutic modalities to target cyclin dependent kinase. Cancers 13, 5506 (2021).Crossref, Medline, Google Scholar6. Martin MP, Endicott JA, Noble MEM. Structure-based discovery of cyclin-dependent protein kinase inhibitors. Essays Biochem. 61(5), 439–452 (2017).Crossref, Medline, Google Scholar7. Hirose Y, Ohkuma Y. Phosphorylation of the C-terminal domain of RNA polymerase II plays central roles in the integrated events of eucaryotic gene expression. J. Biochem. 141(5), 601–608 (2007).Crossref, Medline, CAS, Google Scholar8. Chen R, Keating MJ, Gandhi V, Plunkett W. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 106(7), 2513–2519 (2005).Crossref, Medline, CAS, Google Scholar9. Chen R, Guo L, Chen Y, Jiang Y, Wierda WG, Plunkett W. Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia. Blood 117(1), 156–164 (2011).Crossref, Medline, CAS, Google Scholar10. Lee DJ, Zeidner JF. Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach. Expert Opin. Investig. Drugs 28(11), 989–1001 (2019).Crossref, Medline, CAS, Google Scholar11. Wu T, Qin Z, Tian Y et al. Recent developments in the biology and medicinal chemistry of CDK9 inhibitors: an update. J. Med. Chem. 63(22), 13228–13257 (2020).Crossref, Medline, CAS, Google Scholar12. Robb CM, Contreras JI, Kour S et al. Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC). Chem. Commun. (Camb.) 53(54), 7577–7580 (2017).Crossref, Medline, CAS, Google Scholar13. King HM, Rana S, Kubica SP et al. Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax. Bioorg. Med. Chem. Lett. 43, 128061 (2021).Crossref, Medline, CAS, Google Scholar14. Olson CM, Jiang B, Erb MA et al. Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. Nat. Chem. Biol. 14(2), 163–170 (2018).Crossref, Medline, CAS, Google Scholar15. Bian J, Ren J, Li Y et al. Discovery of wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity. Bioorg. Chem. 81, 373–381 (2018).Crossref, Medline, CAS, Google Scholar16. Lu J, Qian Y, Altieri M et al. Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chem. Biol. 22(6), 755–763 (2015).Crossref, Medline, CAS, Google Scholar17. Hu B, Zhou Y, Sun D et al. PROTACs: new method to degrade transcription regulating proteins. Eur. J. Med. Chem. 207, 112698 (2020).Crossref, Medline, CAS, Google Scholar18. Contreras JI, Robb CM, King HM et al. Chemical genetic screens identify kinase inhibitor combinations that target anti-apoptotic proteins for cancer therapy. ACS Chem. Biol. 13(5), 1148–1152 (2018).Crossref, Medline, CAS, Google Scholar19. Moreau K, Coen M, Zhang AX et al. Proteolysis-targeting chimeras in drug development: a safety perspective. Br. J. Pharmacol. 177(8), 1709–1718 (2020).Crossref, Medline, CAS, Google Scholar20. Qiu X, Li Y, Yu B et al. Discovery of selective CDK9 degraders with enhancing antiproliferative activity through PROTAC conversion. Eur. J. Med. Chem. 211, 113091 (2021).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetails Vol. 14, No. 3 Follow us on social media for the latest updates Metrics Downloaded 325 times History Received 26 July 2021 Accepted 30 September 2021 Published online 24 November 2021 Published in print February 2022 Information© 2021 Newlands PressKeywordscancerCDK9degraderPROTACFinancial & competing interests disclosureL Boghean is supported by National Cancer Institute T32CA009476 training grant. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download" @default.
• W3217012908 created "2021-12-06" @default.
• W3217012908 creator A5010199477 @default.
• W3217012908 creator A5033239597 @default.
• W3217012908 creator A5037333086 @default.
• W3217012908 creator A5067455675 @default.
• W3217012908 date "2022-01-01" @default.
• W3217012908 modified "2023-10-14" @default.
• W3217012908 title "Selective CDK9 degradation using a proteolysis-targeting chimera (PROTAC) strategy" @default.
• W3217012908 cites W1488181101 @default.
• W3217012908 cites W1985970596 @default.
• W3217012908 cites W2046024621 @default.
• W3217012908 cites W2066107979 @default.
• W3217012908 cites W2070603335 @default.
• W3217012908 cites W2151683271 @default.
• W3217012908 cites W2381339736 @default.
• W3217012908 cites W2625751604 @default.
• W3217012908 cites W2767933197 @default.
• W3217012908 cites W2781383440 @default.
• W3217012908 cites W2795510630 @default.
• W3217012908 cites W2888785247 @default.
• W3217012908 cites W2958418325 @default.
• W3217012908 cites W2981095663 @default.
• W3217012908 cites W3004874245 @default.
• W3217012908 cites W3049724121 @default.
• W3217012908 cites W3082785995 @default.
• W3217012908 cites W3111821491 @default.
• W3217012908 cites W3157731448 @default.
• W3217012908 cites W3208631043 @default.
• W3217012908 doi "https://doi.org/10.4155/fmc-2021-0220" @default.
• W3217012908 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34814708" @default.
• W3217012908 hasPublicationYear "2022" @default.
• W3217012908 type Work @default.
• W3217012908 sameAs 3217012908 @default.
• W3217012908 citedByCount "4" @default.
• W3217012908 countsByYear W32170129082022 @default.
• W3217012908 countsByYear W32170129082023 @default.
• W3217012908 crossrefType "journal-article" @default.
• W3217012908 hasAuthorship W3217012908A5010199477 @default.
• W3217012908 hasAuthorship W3217012908A5033239597 @default.
• W3217012908 hasAuthorship W3217012908A5037333086 @default.
• W3217012908 hasAuthorship W3217012908A5067455675 @default.
• W3217012908 hasConcept C121608353 @default.
• W3217012908 hasConcept C126322002 @default.
• W3217012908 hasConcept C161191863 @default.
• W3217012908 hasConcept C2781187634 @default.
• W3217012908 hasConcept C41008148 @default.
• W3217012908 hasConcept C526805850 @default.
• W3217012908 hasConcept C71924100 @default.
• W3217012908 hasConcept C74909509 @default.
• W3217012908 hasConceptScore W3217012908C121608353 @default.
• W3217012908 hasConceptScore W3217012908C126322002 @default.
• W3217012908 hasConceptScore W3217012908C161191863 @default.
• W3217012908 hasConceptScore W3217012908C2781187634 @default.
• W3217012908 hasConceptScore W3217012908C41008148 @default.
• W3217012908 hasConceptScore W3217012908C526805850 @default.
• W3217012908 hasConceptScore W3217012908C71924100 @default.
• W3217012908 hasConceptScore W3217012908C74909509 @default.
• W3217012908 hasIssue "3" @default.
• W3217012908 hasLocation W32170129081 @default.
• W3217012908 hasLocation W32170129082 @default.
• W3217012908 hasOpenAccess W3217012908 @default.
• W3217012908 hasPrimaryLocation W32170129081 @default.
• W3217012908 hasRelatedWork W1767448943 @default.
• W3217012908 hasRelatedWork W2003695917 @default.
• W3217012908 hasRelatedWork W2063875801 @default.
• W3217012908 hasRelatedWork W2096021974 @default.
• W3217012908 hasRelatedWork W2122028967 @default.
• W3217012908 hasRelatedWork W2566237707 @default.
• W3217012908 hasRelatedWork W2899084033 @default.
• W3217012908 hasRelatedWork W4232389330 @default.
• W3217012908 hasRelatedWork W4308890611 @default.
• W3217012908 hasRelatedWork W2588285805 @default.
• W3217012908 hasVolume "14" @default.
• W3217012908 isParatext "false" @default.
• W3217012908 isRetracted "false" @default.
• W3217012908 magId "3217012908" @default.
• W3217012908 workType "article" @default.